| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.847 | 0.002 | 0.847 | 5 Hydroxytryptamine 2C agonist | 0.149 0.005 DBMET00949 | ||
| 0.825 | 0.003 | 0.825 | 5 Hydroxytryptamine agonist | 0.165 0.019 DBMET00949 | ||
| 0.748 | 0.005 | 0.748 | 5 Hydroxytryptamine release stimulant | 0.686 0.008 DBMET00949 0.21 0.113 DBMET00950 | ||
| 0.69 | 0.002 | 0.69 | GABA C receptor agonist | 0.656 0.002 DBMET00949 0.231 0.016 DBMET00950 | ||
| 0.649 | 0.004 | 0.649 | GABA C receptor rho-3 antagonist | 0.439 0.046 DBMET00949 0.301 0.115 DBMET00950 | ||
| 0.636 | 0.004 | 0.636 | Alpha-N-acetylglucosaminidase inhibitor | 0.386 0.01 DBMET00949 0.561 0.004 DBMET00950 | ||
| 0.617 | 0.006 | 0.617 | Superoxide dismutase inhibitor | 0.272 0.062 DBMET00949 0.186 0.134 DBMET00950 | ||
| 0.586 | 0.004 | 0.586 | 5 Hydroxytryptamine 1F antagonist | |||
| 0.598 | 0.019 | 0.598 | Aldehyde oxidase inhibitor | 0.167 0.125 DBMET00950 | ||
| 0.595 | 0.021 | 0.595 | Antiobesity | |||
| 0.603 | 0.036 | 0.603 | Caspase 9 stimulant | 0.431 0.093 DBMET00949 0.307 0.186 DBMET00950 | ||
| 0.572 | 0.011 | 0.572 | Ca2+/calmodulin-dependent protein kinase kinase A inhibitor | 0.467 0.051 DBMET00949 0.297 0.217 DBMET00950 | ||
| 0.54 | 0.005 | 0.54 | Antiadrenergic | |||
| 0.539 | 0.005 | 0.539 | Adrenaline antagonist | |||
| 0.515 | 0.004 | 0.515 | 5 Hydroxytryptamine uptake stimulant | 0.475 0.005 DBMET00949 0.26 0.072 DBMET00950 | ||
| 0.505 | 0.004 | 0.505 | 5 Hydroxytryptamine uptake inhibitor | 0.096 0.028 DBMET00949 | ||
| 0.488 | 0.004 | 0.488 | 5 Hydroxytryptamine 7 antagonist | |||
| 0.491 | 0.01 | 0.491 | Peroxidase inhibitor | 0.112 0.108 DBMET00949 | ||
| 0.479 | 0.007 | 0.479 | Calcium channel activator | 0.334 0.061 DBMET00949 0.251 0.146 DBMET00950 | ||
| 0.499 | 0.033 | 0.499 | 5 Hydroxytryptamine release inhibitor | 0.289 0.178 DBMET00949 | ||
| 0.494 | 0.029 | 0.494 | Vasodilator, peripheral | 0.339 0.078 DBMET00949 0.232 0.142 DBMET00950 | ||
| 0.473 | 0.01 | 0.473 | Ca2+/calmodulin-dependent kinase II alpha inhibitor | |||
| 0.456 | 0.005 | 0.456 | Tyrosine 3 hydroxylase inhibitor | 0.375 0.011 DBMET00949 0.294 0.036 DBMET00950 | ||
| 0.446 | 0.005 | 0.446 | Protein kinase (CaMK, MLCK, PhK, SNF, KIN, NIM1, MAPKAP, POLO, CHK, ULK, RSK-2nd domain) inhibitor | 0.07 0.06 DBMET00949 | ||
| 0.455 | 0.02 | 0.455 | HERG channel blocker | |||
| 0.429 | 0.003 | 0.429 | GABA C receptor antagonist | 0.36 0.004 DBMET00949 0.117 0.055 DBMET00950 | ||
| 0.464 | 0.043 | 0.464 | Calcium channel L-type activator | 0.361 0.109 DBMET00949 | ||
| 0.42 | 0.003 | 0.42 | Protein kinase C mu inhibitor | 0.116 0.044 DBMET00949 | ||
| 0.41 | 0.004 | 0.41 | Ferrochelatase inhibitor | 0.14 0.042 DBMET00949 0.116 0.057 DBMET00950 | ||
| 0.376 | 0.005 | 0.376 | Check point kinase 1 inhibitor | 0.065 0.051 DBMET00949 | ||
| 0.411 | 0.052 | 0.411 | MAP kinase kinase 6 inhibitor | |||
| 0.386 | 0.029 | 0.386 | Potassium channel (Voltage-sensitive) blocker | |||
| 0.363 | 0.009 | 0.363 | Ca2+/calmodulin-dependent kinase IV inhibitor | 0.278 0.038 DBMET00949 | ||
| 0.378 | 0.025 | 0.378 | DNA synthesis inhibitor | 0.287 0.048 DBMET00949 0.325 0.036 DBMET00950 | ||
| 0.416 | 0.067 | 0.416 | Histamine release inhibitor | |||
| 0.372 | 0.027 | 0.372 | Psychostimulant | 0.18 0.093 DBMET00949 | ||
| 0.361 | 0.023 | 0.361 | Cyclic AMP phosphodiesterase inhibitor | 0.183 0.108 DBMET00950 | ||
| 0.364 | 0.025 | 0.364 | Interleukin agonist | 0.266 0.068 DBMET00949 0.176 0.144 DBMET00950 | ||
| 0.337 | 0.004 | 0.337 | MAP-kinase-activated kinase inhibitor | 0.117 0.027 DBMET00949 | ||
| 0.348 | 0.015 | 0.348 | Cyclin-dependent kinase inhibitor | 0.146 0.058 DBMET00949 | ||
| 0.347 | 0.014 | 0.347 | Phospholipase C inhibitor | 0.16 0.087 DBMET00949 0.154 0.099 DBMET00950 | ||
| 0.332 | 0.004 | 0.332 | Adrenaline uptake inhibitor | 0.123 0.014 DBMET00949 | ||
| 0.33 | 0.003 | 0.33 | GABA C receptor rho-1 antagonist | 0.28 0.004 DBMET00949 0.094 0.071 DBMET00950 | ||
| 0.372 | 0.045 | 0.372 | Vasodilator, coronary | 0.257 0.128 DBMET00949 0.263 0.122 DBMET00950 | ||
| 0.33 | 0.004 | 0.33 | Cyclin-dependent kinase 4 inhibitor | 0.07 0.041 DBMET00949 | ||
| 0.327 | 0.004 | 0.327 | CXC chemokine 4 receptor antagonist | 0.084 0.029 DBMET00949 | ||
| 0.325 | 0.005 | 0.325 | Activin receptor-like kinase 4 inhibitor | |||
| 0.322 | 0.005 | 0.322 | GABA C receptor rho-2 antagonist | 0.202 0.028 DBMET00949 | ||
| 0.327 | 0.017 | 0.327 | MAP-kinase-activated kinase 5 inhibitor | |||
| 0.326 | 0.017 | 0.326 | 5 Hydroxytryptamine 1E antagonist | 0.256 0.068 DBMET00949 | ||
| 0.315 | 0.008 | 0.315 | Nitric-oxide synthase stimulant | 0.233 0.045 DBMET00949 0.213 0.07 DBMET00950 | ||
| 0.31 | 0.004 | 0.31 | 5 Hydroxytryptamine 3E antagonist | 0.23 0.027 DBMET00949 | ||
| 0.305 | 0.004 | 0.305 | MAP-kinase-activated kinase 2 inhibitor | 0.111 0.023 DBMET00949 | ||
| 0.304 | 0.005 | 0.304 | ALK inhibitor | |||
| 0.301 | 0.004 | 0.301 | 5 Hydroxytryptamine 3A agonist | 0.182 0.021 DBMET00949 | ||
| 0.304 | 0.01 | 0.304 | UDP-glucose 4-epimerase inhibitor | 0.159 0.026 DBMET00949 0.2 0.018 DBMET00950 | ||
| 0.294 | 0.005 | 0.294 | Pim-1 kinase inhibitor | |||
| 0.314 | 0.029 | 0.314 | RNA-directed DNA polymerase inhibitor | 0.212 0.083 DBMET00949 0.191 0.114 DBMET00950 | ||
| 0.31 | 0.032 | 0.31 | MAP kinase kinase 2 inhibitor | |||
| 0.308 | 0.031 | 0.308 | Anesthetic general | 0.144 0.12 DBMET00949 0.134 0.132 DBMET00950 | ||
| 0.321 | 0.047 | 0.321 | Insulysin inhibitor | 0.234 0.112 DBMET00949 | ||
| 0.279 | 0.004 | 0.279 | Protein kinase C delta inhibitor | |||
| 0.298 | 0.034 | 0.298 | Gastrin inhibitor | 0.225 0.112 DBMET00949 | ||
| 0.267 | 0.003 | 0.267 | Nicotinic receptor alpha4 subunit antagonist | 0.094 0.009 DBMET00949 | ||
| 0.283 | 0.021 | 0.283 | Tyrosine-protein kinase receptor FLT3 inhibitor | |||
| 0.264 | 0.008 | 0.264 | 5 Hydroxytryptamine 1 agonist | |||
| 0.272 | 0.016 | 0.272 | Succinate dehydrogenase inhibitor | 0.167 0.084 DBMET00949 0.176 0.073 DBMET00950 | ||
| 0.258 | 0.005 | 0.258 | Alcohol oxidase inhibitor | 0.06 0.035 DBMET00949 0.137 0.012 DBMET00950 | ||
| 0.256 | 0.007 | 0.256 | Porphobilinogen synthase inhibitor | 0.069 0.056 DBMET00949 | ||
| 0.274 | 0.026 | 0.274 | I kappa B kinase epsilon inhibitor | 0.142 0.129 DBMET00949 | ||
| 0.253 | 0.01 | 0.253 | Adenylate kinase inhibitor | 0.112 0.051 DBMET00949 0.165 0.022 DBMET00950 | ||
| 0.259 | 0.019 | 0.259 | Cyclin-dependent kinase 7 inhibitor | |||
| 0.243 | 0.004 | 0.243 | Toll-Like receptor 7 antagonist | 0.067 0.049 DBMET00949 | ||
| 0.243 | 0.004 | 0.243 | CDK4/cyclin D1 inhibitor | |||
| 0.264 | 0.027 | 0.264 | Tumour necrosis factor antagonist | |||
| 0.241 | 0.004 | 0.241 | Protein kinase C alpha inhibitor | |||
| 0.259 | 0.024 | 0.259 | 3C-like protease (Human coronavirus) inhibitor | 0.163 0.082 DBMET00949 | ||
| 0.243 | 0.008 | 0.243 | NADH dehydrogenase inhibitor | 0.097 0.047 DBMET00949 0.136 0.021 DBMET00950 | ||
| 0.3 | 0.066 | 0.3 | Hypoxia-inducible factor 1 alpha inhibitor | |||
| 0.242 | 0.01 | 0.242 | UDP-N-acetylglucosamine 1-carboxyvinyltransferase inhibitor | 0.131 0.033 DBMET00949 0.156 0.025 DBMET00950 | ||
| 0.236 | 0.008 | 0.236 | Triose-phosphate isomerase inhibitor | 0.104 0.044 DBMET00949 0.157 0.018 DBMET00950 | ||
| 0.232 | 0.005 | 0.232 | Cyclin B3 inhibitor | 0.088 0.034 DBMET00949 | ||
| 0.288 | 0.062 | 0.288 | DNA damaging | |||
| 0.305 | 0.085 | 0.305 | Antithrombotic | 0.241 0.133 DBMET00950 | ||
| 0.258 | 0.039 | 0.258 | Glyceraldehyde-3-phosphate dehydrogenase inhibitor | 0.218 0.059 DBMET00949 0.248 0.044 DBMET00950 | ||
| 0.306 | 0.087 | 0.306 | Cholesterol antagonist | 0.188 0.176 DBMET00950 | ||
| 0.222 | 0.005 | 0.933 | Poly(ADP-ribose) polymerase inhibitor | 0.933 0.001 DBMET00949 | DBMET00949 | |
| 0.227 | 0.011 | 0.227 | Polo-like kinase-4 inhibitor | |||
| 0.223 | 0.007 | 0.223 | Adenylate cyclase stimulant | 0.17 0.035 DBMET00949 0.166 0.04 DBMET00950 | ||
| 0.257 | 0.044 | 0.257 | DNA methyltransferase I inhibitor | 0.182 0.079 DBMET00949 | ||
| 0.234 | 0.024 | 0.234 | Toll-Like receptor 9 antagonist | 0.163 0.055 DBMET00949 | ||
| 0.215 | 0.009 | 0.215 | Creatine kinase inhibitor | 0.104 0.055 DBMET00949 0.171 0.017 DBMET00950 | ||
| 0.224 | 0.019 | 0.224 | Alpha 2b adrenoreceptor antagonist | 0.103 0.072 DBMET00949 | ||
| 0.216 | 0.011 | 0.216 | Histidine decarboxylase inhibitor | 0.077 0.045 DBMET00949 0.063 0.058 DBMET00950 | ||
| 0.238 | 0.037 | 0.238 | Protein kinase C nu inhibitor | |||
| 0.206 | 0.005 | 0.206 | I kappa B kinase 1 inhibitor | |||
| 0.248 | 0.049 | 0.248 | DNA methylase inhibitor | 0.187 0.088 DBMET00949 | ||
| 0.203 | 0.005 | 0.203 | Protein kinase C iota inhibitor | 0.103 0.018 DBMET00949 | ||
| 0.203 | 0.005 | 0.203 | CDK4/cyclin D inhibitor | |||
| 0.24 | 0.043 | 0.24 | Focal adhesion kinase 2 inhibitor | |||
| 0.219 | 0.023 | 0.219 | Cyclin-dependent kinase 1 inhibitor | 0.168 0.034 DBMET00949 | ||
| 0.198 | 0.003 | 0.198 | Alpha 1b adrenoreceptor agonist | |||
| 0.227 | 0.032 | 0.227 | Acetylcholine M1 receptor antagonist | 0.223 0.033 DBMET00949 0.128 0.098 DBMET00950 | ||
| 0.201 | 0.009 | 0.201 | 5 Hydroxytryptamine 1A agonist | |||
| 0.196 | 0.004 | 0.196 | Alpha 2 adrenoreceptor agonist | 0.112 0.012 DBMET00949 | ||
| 0.2 | 0.009 | 0.2 | Prolactin inhibitor | 0.145 0.024 DBMET00949 | ||
| 0.236 | 0.047 | 0.236 | Neurotrophic factor enhancer | |||
| 0.191 | 0.003 | 0.191 | Motilin receptor agonist | 0.029 0.01 DBMET00949 | ||
| 0.191 | 0.005 | 0.925 | Poly(ADP-ribose) polymerase 1 inhibitor | 0.925 0.001 DBMET00949 | DBMET00949 | |
| 0.193 | 0.006 | 0.193 | Biliverdin reductase inhibitor | 0.065 0.036 DBMET00949 0.095 0.02 DBMET00950 | ||
| 0.216 | 0.03 | 0.216 | Activin receptor-like kinase 2 inhibitor | |||
| 0.2 | 0.014 | 0.2 | Protein kinase C gamma inhibitor | 0.101 0.075 DBMET00949 | ||
| 0.195 | 0.009 | 0.195 | Alpha adrenoreceptor agonist | 0.08 0.038 DBMET00949 | ||
| 0.212 | 0.027 | 0.212 | Toll-Like receptor antagonist | 0.119 0.086 DBMET00949 | ||
| 0.215 | 0.03 | 0.215 | NADPH oxidase inhibitor | |||
| 0.193 | 0.008 | 0.193 | Carbamoyl phosphate synthetase inhibitor | 0.104 0.019 DBMET00949 0.133 0.013 DBMET00950 | ||
| 0.197 | 0.012 | 0.197 | HIV-1 integrase (Overall Integration) inhibitor | 0.085 0.071 DBMET00949 | ||
| 0.184 | 0.005 | 0.184 | Nicotinic alpha4beta2 receptor antagonist | 0.132 0.012 DBMET00949 | ||
| 0.189 | 0.009 | 0.189 | CDK1/cyclin B1 inhibitor | 0.154 0.015 DBMET00949 | ||
| 0.215 | 0.036 | 0.215 | Vascular endothelial growth factor 3 antagonist | |||
| 0.2 | 0.021 | 0.2 | CF transmembrane conductance regulator agonist | 0.138 0.099 DBMET00949 0.146 0.083 DBMET00950 | ||
| 0.188 | 0.01 | 0.188 | Electrolyte absorption antagonist | |||
| 0.197 | 0.019 | 0.197 | CDK/cyclin complex inhibitor | 0.081 0.067 DBMET00949 | ||
| 0.185 | 0.008 | 0.185 | Phenylalanine 4-hydroxylase inhibitor | |||
| 0.205 | 0.028 | 0.205 | Catenin beta inhibitor | |||
| 0.182 | 0.006 | 0.182 | Ca2+-transporting ATPase inhibitor | 0.153 0.035 DBMET00949 0.168 0.014 DBMET00950 | ||
| 0.177 | 0.001 | 0.177 | Alpha 1L adrenoreceptor agonist | 0.042 0.032 DBMET00949 | ||
| 0.19 | 0.015 | 0.19 | Protein kinase A inhibitor | |||
| 0.235 | 0.061 | 0.235 | Ca2+/calmodulin-dependent protein kinase inhibitor | |||
| 0.19 | 0.016 | 0.19 | Acetylcholine agonist | 0.156 0.024 DBMET00949 | ||
| 0.202 | 0.029 | 0.202 | Cell wall synthesis inhibitor | 0.159 0.057 DBMET00949 0.116 0.106 DBMET00950 | ||
| 0.214 | 0.041 | 0.214 | Cytidine deaminase inhibitor | |||
| 0.204 | 0.032 | 0.581 | Death-associated protein kinase 2 inhibitor | 0.581 0.002 DBMET00949 | DBMET00949 | |
| 0.176 | 0.004 | 0.176 | 5 Hydroxytryptamine 3 agonist | 0.095 0.017 DBMET00949 | ||
| 0.189 | 0.019 | 0.189 | Alpha 2 adrenoreceptor antagonist | 0.098 0.05 DBMET00949 | ||
| 0.18 | 0.01 | 0.18 | Acetylcholine nicotinic agonist | 0.137 0.021 DBMET00949 | ||
| 0.185 | 0.016 | 0.185 | Alpha 2a adrenoreceptor antagonist | 0.08 0.049 DBMET00949 | ||
| 0.181 | 0.013 | 0.362 | Death-associated protein kinase 1 inhibitor | 0.362 0.003 DBMET00949 | DBMET00949 | |
| 0.237 | 0.069 | 0.237 | Neuropeptide Y2 antagonist | 0.208 0.105 DBMET00949 | ||
| 0.256 | 0.089 | 0.256 | Spasmolytic | |||
| 0.208 | 0.041 | 0.208 | Amylase inhibitor | 0.109 0.088 DBMET00950 | ||
| 0.2 | 0.033 | 0.2 | Arachidonic acid antagonist | 0.192 0.041 DBMET00950 | ||
| 0.187 | 0.02 | 0.187 | Check point kinase 2 inhibitor | |||
| 0.174 | 0.008 | 0.174 | Histamine N-methyltransferase inhibitor | 0.078 0.069 DBMET00949 | ||
| 0.17 | 0.004 | 0.17 | 5 Hydroxytryptamine 1B agonist | |||
| 0.18 | 0.015 | 0.18 | Acetylcholine nicotinic antagonist | 0.115 0.032 DBMET00949 | ||
| 0.183 | 0.018 | 0.183 | Interleukin 8 antagonist | 0.119 0.062 DBMET00949 | ||
| 0.192 | 0.027 | 0.192 | Toll-Like receptor 2 antagonist | 0.109 0.091 DBMET00949 | ||
| 0.199 | 0.036 | 0.199 | Cyclin-dependent kinase 8 inhibitor | 0.133 0.099 DBMET00949 | ||
| 0.169 | 0.006 | 0.169 | Protein kinase C eta inhibitor | |||
| 0.199 | 0.035 | 0.199 | Neurotensin receptor agonist | 0.164 0.072 DBMET00949 | ||
| 0.187 | 0.024 | 0.187 | Nav1.6 sodium channel blocker | |||
| 0.183 | 0.021 | 0.183 | Sphingosine 1-phosphate receptor 5 antagonist | 0.138 0.084 DBMET00949 | ||
| 0.166 | 0.004 | 0.166 | Somatostatin 4 agonist | 0.085 0.008 DBMET00949 | ||
| 0.166 | 0.005 | 0.166 | Glycine receptor antagonist | 0.104 0.029 DBMET00949 0.092 0.041 DBMET00950 | ||
| 0.166 | 0.005 | 0.166 | Alpha 2d adrenoreceptor antagonist | |||
| 0.171 | 0.01 | 0.171 | Acetylcholine M3 receptor agonist | 0.126 0.032 DBMET00949 | ||
| 0.174 | 0.014 | 0.174 | Phosphofructokinase-1 inhibitor | 0.079 0.041 DBMET00949 0.149 0.018 DBMET00950 | ||
| 0.297 | 0.138 | 0.324 | Antibacterial | 0.324 0.118 DBMET00950 | DBMET00950 | |
| 0.167 | 0.008 | 0.167 | Acyl-CoA dehydrogenase inhibitor | 0.047 0.046 DBMET00949 0.087 0.02 DBMET00950 | ||
| 0.162 | 0.005 | 0.162 | 5 Hydroxytryptamine 2A agonist | 0.089 0.02 DBMET00949 | ||
| 0.202 | 0.045 | 0.202 | Ca2+/calmodulin-dependent kinase II delta inhibitor | |||
| 0.157 | 0.003 | 0.157 | Dopamine D5 agonist | 0.117 0.004 DBMET00949 0.04 0.027 DBMET00950 | ||
| 0.17 | 0.016 | 0.17 | Nitric-oxide synthase inhibitor | 0.126 0.034 DBMET00949 | ||
| 0.176 | 0.023 | 0.176 | Alpha 2c adrenoreceptor antagonist | 0.112 0.055 DBMET00949 | ||
| 0.156 | 0.004 | 0.156 | Cyclin D3 inhibitor | |||
| 0.163 | 0.014 | 0.163 | Glutamate dehydrogenase inhibitor | 0.082 0.043 DBMET00949 0.102 0.029 DBMET00950 | ||
| 0.166 | 0.017 | 0.166 | Protein kinase C zeta inhibitor | 0.095 0.057 DBMET00949 | ||
| 0.167 | 0.019 | 0.167 | Calcium antagonist | |||
| 0.159 | 0.011 | 0.159 | Neuronal nicotinic receptor antagonist | 0.103 0.023 DBMET00949 | ||
| 0.157 | 0.011 | 0.157 | Argininosuccinate synthase inhibitor | 0.071 0.03 DBMET00949 0.087 0.023 DBMET00950 | ||
| 0.176 | 0.03 | 0.176 | Cyclooxygenase 3 inhibitor | 0.14 0.058 DBMET00950 | ||
| 0.183 | 0.037 | 0.183 | Cholinergic antagonist | 0.156 0.049 DBMET00949 | ||
| 0.206 | 0.061 | 0.206 | Histone acetyltransferase inhibitor | |||
| 0.228 | 0.083 | 0.416 | Vasodilator | 0.156 0.149 DBMET00949 0.416 0.02 DBMET00950 | DBMET00950 | |
| 0.159 | 0.014 | 0.159 | Inducible nitric-oxide synthase inhibitor | 0.107 0.031 DBMET00949 | ||
| 0.176 | 0.031 | 0.176 | Cystathionine beta-synthase inhibitor | 0.092 0.087 DBMET00950 | ||
| 0.149 | 0.005 | 0.149 | 5 Hydroxytryptamine 2 agonist | 0.056 0.032 DBMET00949 | ||
| 0.147 | 0.003 | 0.147 | Phospholipase D inhibitor | 0.086 0.026 DBMET00949 | ||
| 0.173 | 0.029 | 0.173 | Aminopeptidase B inhibitor | 0.116 0.055 DBMET00949 | ||
| 0.16 | 0.017 | 0.16 | Transcription factor STAT6 inhibitor | 0.11 0.08 DBMET00949 | ||
| 0.18 | 0.037 | 0.18 | Acetylcholine antagonist | 0.153 0.049 DBMET00949 | ||
| 0.159 | 0.017 | 0.159 | DOPA decarboxylase inhibitor | 0.124 0.041 DBMET00949 0.1 0.076 DBMET00950 | ||
| 0.164 | 0.021 | 0.164 | DNA repair enzyme inhibitor | 0.114 0.085 DBMET00949 | ||
| 0.166 | 0.024 | 0.166 | Sphingosine 1-phosphate receptor 2 antagonist | |||
| 0.238 | 0.096 | 0.238 | Transcription factor STAT inhibitor | |||
| 0.172 | 0.031 | 0.277 | Aurora-C kinase inhibitor | 0.277 0.006 DBMET00949 | DBMET00949 | |
| 0.146 | 0.005 | 0.146 | Acetylcholine M5 receptor agonist | 0.084 0.031 DBMET00949 | ||
| 0.185 | 0.044 | 0.185 | Ribosomal protein S6 kinase inhibitor | |||
| 0.147 | 0.006 | 0.147 | Protein kinase C epsilon inhibitor | |||
| 0.144 | 0.004 | 0.144 | Myc inhibitor | 0.094 0.009 DBMET00949 | ||
| 0.15 | 0.01 | 0.15 | CXC chemokine receptor antagonist | |||
| 0.148 | 0.008 | 0.148 | Viral attachment inhibitor | 0.088 0.036 DBMET00949 | ||
| 0.152 | 0.013 | 0.152 | Glutamate decarboxylase inhibitor | 0.073 0.052 DBMET00949 0.078 0.046 DBMET00950 | ||
| 0.16 | 0.021 | 0.16 | Sphingosine 1-phosphate receptor 2 agonist | |||
| 0.153 | 0.015 | 0.153 | Acetylcholine release stimulant | 0.107 0.071 DBMET00949 0.136 0.028 DBMET00950 | ||
| 0.187 | 0.049 | 0.187 | ATPase inhibitor | |||
| 0.148 | 0.01 | 0.148 | Acetylcholine muscarinic agonist | 0.114 0.015 DBMET00949 | ||
| 0.171 | 0.034 | 0.171 | MAP3K9 inhibitor | |||
| 0.165 | 0.03 | 0.165 | Falcipain 3 inhibitor | |||
| 0.137 | 0.003 | 0.137 | Alpha 1a adrenoreceptor agonist | |||
| 0.161 | 0.027 | 0.161 | Heat shock protein 70 antagonist | 0.133 0.107 DBMET00949 | ||
| 0.19 | 0.056 | 0.19 | Antipruritic | |||
| 0.165 | 0.031 | 0.165 | Pregnane X receptor agonist | 0.143 0.067 DBMET00949 | ||
| 0.216 | 0.083 | 0.216 | Potassium channel blocker | |||
| 0.165 | 0.032 | 0.165 | Cyclin-dependent kinase 2 inhibitor | |||
| 0.14 | 0.008 | 0.14 | Glycine receptor agonist | 0.099 0.022 DBMET00949 0.083 0.035 DBMET00950 | ||
| 0.203 | 0.071 | 0.203 | Proto-oncogene tyrosine-protein kinase Fyn inhibitor | |||
| 0.151 | 0.019 | 0.151 | Rho-associated kinase inhibitor | |||
| 0.135 | 0.004 | 0.135 | Mannosidase inhibitor | 0.08 0.009 DBMET00949 0.081 0.008 DBMET00950 | ||
| 0.134 | 0.003 | 0.134 | 5 Hydroxytryptamine 2B agonist | 0.052 0.012 DBMET00949 | ||
| 0.144 | 0.014 | 0.144 | Lanosterol 14 alpha demethylase inhibitor | 0.09 0.073 DBMET00949 0.111 0.04 DBMET00950 | ||
| 0.244 | 0.114 | 0.244 | Nootropic | |||
| 0.175 | 0.046 | 0.175 | Hemostatic | |||
| 0.165 | 0.037 | 0.165 | Cathepsin H inhibitor | 0.118 0.078 DBMET00949 0.111 0.088 DBMET00950 | ||
| 0.133 | 0.005 | 0.133 | Protein kinase C beta inhibitor | 0.077 0.034 DBMET00949 | ||
| 0.136 | 0.009 | 0.136 | Acetylcholine M1 receptor agonist | 0.105 0.012 DBMET00949 | ||
| 0.137 | 0.009 | 0.137 | Mannitol-1-phosphate 5-dehydrogenase inhibitor | 0.079 0.021 DBMET00950 | ||
| 0.151 | 0.024 | 0.151 | Beta glucuronidase inhibitor | |||
| 0.155 | 0.03 | 0.155 | Chemokine receptor antagonist | |||
| 0.173 | 0.047 | 0.173 | Mannose-6-phosphate isomerase inhibitor | |||
| 0.13 | 0.005 | 0.13 | GABA B receptor agonist | 0.081 0.04 DBMET00949 0.081 0.04 DBMET00950 | ||
| 0.128 | 0.003 | 0.128 | Alpha 1d adrenoreceptor agonist | 0.038 0.028 DBMET00949 | ||
| 0.138 | 0.013 | 0.138 | Glutamate release inhibitor | |||
| 0.136 | 0.013 | 0.136 | Interferon agonist | |||
| 0.16 | 0.037 | 0.16 | 5 Hydroxytryptamine 2B antagonist | |||
| 0.132 | 0.01 | 0.132 | Granulocyte macrophage colony stimulating factor agonist | 0.083 0.067 DBMET00949 | ||
| 0.175 | 0.053 | 0.175 | Hexokinase inhibitor | |||
| 0.17 | 0.047 | 0.17 | Nav1.2 sodium channel blocker | |||
| 0.16 | 0.038 | 0.16 | Acetylcholine muscarinic antagonist | 0.142 0.049 DBMET00949 | ||
| 0.152 | 0.03 | 0.152 | Photosensitizer | |||
| 0.128 | 0.006 | 0.128 | Cyclin B1 inhibitor | |||
| 0.137 | 0.015 | 0.137 | Aminopeptidase I inhibitor | 0.074 0.049 DBMET00949 0.092 0.033 DBMET00950 | ||
| 0.178 | 0.057 | 0.178 | Cholinergic | 0.161 0.069 DBMET00950 | ||
| 0.165 | 0.044 | 0.165 | Neuropeptide Y1 antagonist | 0.153 0.061 DBMET00949 | ||
| 0.127 | 0.006 | 0.127 | Histamine agonist | 0.066 0.022 DBMET00949 | ||
| 0.124 | 0.004 | 0.124 | MAP kinase kinase 7 inhibitor | 0.099 0.013 DBMET00949 0.095 0.018 DBMET00950 | ||
| 0.159 | 0.039 | 0.159 | Adenylate cyclase inhibitor | |||
| 0.245 | 0.125 | 0.245 | Interleukin 2 agonist | 0.242 0.128 DBMET00950 | ||
| 0.125 | 0.005 | 0.125 | Protein kinase C theta inhibitor | |||
| 0.139 | 0.019 | 0.139 | CYP2A6 inhibitor | |||
| 0.173 | 0.054 | 0.173 | Protein kinase stimulant | 0.112 0.102 DBMET00949 0.126 0.087 DBMET00950 | ||
| 0.127 | 0.008 | 0.127 | Nicotinic receptor alpha7 subunit antagonist | 0.08 0.017 DBMET00949 | ||
| 0.126 | 0.008 | 0.126 | 5 Hydroxytryptamine 3A antagonist | 0.067 0.046 DBMET00949 | ||
| 0.139 | 0.022 | 0.139 | Pim-3 kinase inhibitor | 0.097 0.049 DBMET00949 | ||
| 0.136 | 0.018 | 0.136 | Glutamate (mGluR7) agonist | 0.09 0.083 DBMET00949 | ||
| 0.136 | 0.019 | 0.136 | Adrenaline agonist | |||
| 0.125 | 0.008 | 0.125 | Dopamine transporter inhibitor | 0.07 0.021 DBMET00949 | ||
| 0.119 | 0.002 | 0.119 | Phenylethanolamine N methyltransferase inhibitor | 0.082 0.004 DBMET00949 | ||
| 0.144 | 0.028 | 0.144 | Catalase inhibitor | |||
| 0.223 | 0.108 | 0.223 | Transcription factor STAT3 inhibitor | |||
| 0.138 | 0.022 | 0.138 | MAP kinase kinase 1 inhibitor | |||
| 0.131 | 0.017 | 0.131 | Bromodomain-containing protein 2 inhibitor | 0.088 0.058 DBMET00949 | ||
| 0.119 | 0.005 | 0.119 | Exportin-1 inhibitor | |||
| 0.118 | 0.005 | 0.118 | Alpha-mannosidase inhibitor | 0.078 0.012 DBMET00949 0.094 0.007 DBMET00950 | ||
| 0.184 | 0.071 | 0.184 | LIM domain kinase 1 inhibitor | |||
| 0.118 | 0.005 | 0.118 | Poly(ADP-ribose) polymerase 2 inhibitor | |||
| 0.127 | 0.013 | 0.127 | Carbonic anhydrase stimulant | |||
| 0.168 | 0.055 | 0.168 | Protein kinase (CK1) inhibitor | |||
| 0.121 | 0.008 | 0.121 | CC chemokine 5 receptor agonist | 0.115 0.01 DBMET00949 | ||
| 0.257 | 0.145 | 0.257 | Calpain 2 inhibitor | |||
| 0.155 | 0.043 | 0.155 | 5 Hydroxytryptamine 2 antagonist | |||
| 0.22 | 0.109 | 0.22 | Immunostimulant | |||
| 0.196 | 0.085 | 0.196 | Anticonvulsant | |||
| 0.117 | 0.006 | 0.117 | Cyclin-dependent kinase 6 inhibitor | 0.087 0.017 DBMET00949 | ||
| 0.144 | 0.033 | 0.144 | Carbonic anhydrase XV inhibitor | |||
| 0.124 | 0.013 | 0.124 | Caspase 7 inhibitor | |||
| 0.115 | 0.005 | 0.115 | Nicotinic alpha3beta2 receptor antagonist | 0.104 0.007 DBMET00949 | ||
| 0.146 | 0.037 | 0.146 | Sphingosine 1-phosphate receptor 4 antagonist | |||
| 0.168 | 0.059 | 0.168 | Interferon gamma antagonist | 0.151 0.076 DBMET00950 | ||
| 0.211 | 0.103 | 0.211 | Calpain inhibitor | |||
| 0.189 | 0.081 | 0.285 | Death-associated protein kinase 3 inhibitor | 0.285 0.042 DBMET00949 | DBMET00949 | |
| 0.157 | 0.049 | 0.157 | Sodium channel (voltage-gated) blocker | |||
| 0.118 | 0.011 | 0.118 | NMDA 2C receptor antagonist | 0.111 0.013 DBMET00949 | ||
| 0.116 | 0.009 | 0.116 | Nicotinic neuronal receptor agonist | 0.086 0.018 DBMET00949 | ||
| 0.111 | 0.004 | 0.111 | Ryanodine receptor antagonist | 0.066 0.023 DBMET00949 0.058 0.044 DBMET00950 | ||
| 0.136 | 0.03 | 0.136 | 5 Hydroxytryptamine 2C antagonist | |||
| 0.142 | 0.037 | 0.142 | Mucolytic | 0.102 0.075 DBMET00950 | ||
| 0.113 | 0.008 | 0.129 | Cyclin B inhibitor | 0.129 0.006 DBMET00949 | DBMET00949 | |
| 0.117 | 0.013 | 0.117 | Alpha 1 adrenoreceptor agonist | |||
| 0.106 | 0.003 | 0.106 | Nicotinic alpha4 receptor agonist | 0.047 0.004 DBMET00949 | ||
| 0.121 | 0.017 | 0.121 | Acetylcholine M4 receptor antagonist | 0.09 0.037 DBMET00949 | ||
| 0.112 | 0.009 | 0.112 | Interferon inducer | |||
| 0.162 | 0.059 | 0.162 | Thiol protease inhibitor | |||
| 0.108 | 0.006 | 0.108 | Cyclin D1 inhibitor | |||
| 0.113 | 0.012 | 0.113 | 5 Hydroxytryptamine 6 antagonist | 0.057 0.039 DBMET00949 | ||
| 0.108 | 0.007 | 0.108 | Glucosylceramidase inhibitor | 0.058 0.034 DBMET00949 0.054 0.04 DBMET00950 | ||
| 0.15 | 0.049 | 0.15 | 5 Hydroxytryptamine antagonist | |||
| 0.237 | 0.137 | 0.237 | Transcription factor NF kappa B inhibitor | |||
| 0.13 | 0.03 | 0.13 | Phosphodiesterase 7B inhibitor | |||
| 0.13 | 0.031 | 0.13 | Anabolic | 0.088 0.081 DBMET00949 0.123 0.037 DBMET00950 | ||
| 0.11 | 0.011 | 0.11 | Vanilloid 4 agonist | 0.095 0.02 DBMET00949 0.07 0.063 DBMET00950 | ||
| 0.122 | 0.023 | 0.122 | Phosphodiesterase 6D inhibitor | |||
| 0.136 | 0.037 | 0.136 | Nav1.5 sodium channel blocker | |||
| 0.157 | 0.058 | 0.157 | Proto-oncogene tyrosine-protein kinase Yes inhibitor | |||
| 0.106 | 0.007 | 0.106 | Ca(v)3.2 blocker | |||
| 0.108 | 0.009 | 0.108 | S-adenosyl-L-methionine decarboxylase inhibitor | 0.08 0.037 DBMET00949 0.075 0.047 DBMET00950 | ||
| 0.117 | 0.019 | 0.117 | mTOR complex 2 inhibitor | 0.079 0.072 DBMET00949 | ||
| 0.147 | 0.049 | 0.147 | Nav1.3 sodium channel blocker | |||
| 0.156 | 0.059 | 0.156 | MAP kinase 3 inhibitor | 0.133 0.099 DBMET00949 | ||
| 0.104 | 0.007 | 0.104 | Sphingosine kinase 2 inhibitor | 0.075 0.018 DBMET00949 0.077 0.017 DBMET00950 | ||
| 0.109 | 0.014 | 0.109 | 5 Hydroxytryptamine 5A antagonist | 0.06 0.045 DBMET00949 | ||
| 0.103 | 0.008 | 0.103 | Toll-Like receptor 8 antagonist | 0.052 0.039 DBMET00949 | ||
| 0.102 | 0.008 | 0.102 | Aconitate hydratase inhibitor | 0.047 0.044 DBMET00950 | ||
| 0.131 | 0.037 | 0.131 | Carbonic anhydrase III inhibitor | |||
| 0.101 | 0.007 | 0.101 | Cyclin H inhibitor | 0.07 0.028 DBMET00949 | ||
| 0.103 | 0.009 | 0.103 | Glutamate (mGluR6) antagonist | 0.074 0.032 DBMET00949 0.069 0.041 DBMET00950 | ||
| 0.096 | 0.003 | 0.096 | Imidazoline I1 receptor antagonist | 0.032 0.006 DBMET00949 | ||
| 0.146 | 0.053 | 0.146 | MAP kinase kinase inhibitor | |||
| 0.115 | 0.022 | 0.115 | Myeloperoxidase inhibitor | |||
| 0.183 | 0.091 | 0.183 | Ca2+/calmodulin-dependent kinase II beta inhibitor | |||
| 0.109 | 0.016 | 0.109 | Estrogen-related receptor beta agonist | 0.077 0.076 DBMET00950 | ||
| 0.097 | 0.005 | 0.097 | Purinergic P2X4 antagonist | |||
| 0.106 | 0.014 | 0.106 | NMDA receptor glycine site agonist | 0.087 0.023 DBMET00949 | ||
| 0.124 | 0.032 | 0.124 | Interleukin 1 beta converting enzyme inhibitor | |||
| 0.113 | 0.021 | 0.113 | Na+ K+ transporting ATPase inhibitor | 0.096 0.035 DBMET00949 0.103 0.029 DBMET00950 | ||
| 0.106 | 0.015 | 0.106 | Ornithine carbamoyltransferase inhibitor | 0.052 0.037 DBMET00949 0.061 0.031 DBMET00950 | ||
| 0.11 | 0.019 | 0.11 | D-Ala-D-Ala ligase inhibitor | |||
| 0.096 | 0.005 | 0.096 | Histamine H4 receptor antagonist | 0.074 0.01 DBMET00949 | ||
| 0.134 | 0.044 | 0.134 | TRPA1 agonist | |||
| 0.107 | 0.017 | 0.107 | NMDA receptor agonist | 0.098 0.02 DBMET00949 | ||
| 0.104 | 0.014 | 0.104 | 5 Hydroxytryptamine 5 antagonist | 0.052 0.051 DBMET00949 | ||
| 0.136 | 0.046 | 0.136 | Microtubule formation inhibitor | |||
| 0.093 | 0.004 | 0.093 | Dopamine beta hydroxylase inhibitor | |||
| 0.14 | 0.051 | 0.14 | Vanilloid 1 agonist | |||
| 0.14 | 0.052 | 0.14 | Alkylator | 0.097 0.091 DBMET00949 0.123 0.066 DBMET00950 | ||
| 0.096 | 0.008 | 0.096 | Epithelial sodium channel blocker | 0.059 0.03 DBMET00949 | ||
| 0.113 | 0.025 | 0.113 | Histamine H2 receptor antagonist | 0.079 0.067 DBMET00949 | ||
| 0.131 | 0.043 | 0.131 | Alpha adrenoreceptor antagonist | |||
| 0.091 | 0.003 | 0.091 | Alpha 2a adrenoreceptor agonist | |||
| 0.116 | 0.028 | 0.116 | I kappa B kinase inhibitor | |||
| 0.141 | 0.053 | 0.141 | Aldehyde dehydrogenase inhibitor | |||
| 0.137 | 0.05 | 0.137 | Beta amyloid protein antagonist | |||
| 0.096 | 0.009 | 0.096 | Cyclin B2 inhibitor | 0.093 0.01 DBMET00949 | ||
| 0.095 | 0.008 | 0.095 | Corticotropin releasing factor 2 receptor antagonist | 0.058 0.051 DBMET00949 | ||
| 0.106 | 0.02 | 0.106 | 5 Hydroxytryptamine 1D antagonist | 0.058 0.051 DBMET00949 | ||
| 0.094 | 0.008 | 0.094 | 5 Hydroxytryptamine 7 agonist | 0.078 0.014 DBMET00949 | ||
| 0.103 | 0.017 | 0.103 | 5 Hydroxytryptamine 3 antagonist | 0.053 0.044 DBMET00949 | ||
| 0.094 | 0.009 | 0.094 | MDM2 inhibitor | |||
| 0.106 | 0.021 | 0.106 | 5 Hydroxytryptamine 1B antagonist | |||
| 0.094 | 0.009 | 0.094 | Sphingosine kinase inhibitor | 0.083 0.014 DBMET00949 0.071 0.023 DBMET00950 | ||
| 0.159 | 0.074 | 0.159 | Polo-like kinase-3 inhibitor | |||
| 0.09 | 0.005 | 0.09 | Adenylate cyclase 1 inhibitor | 0.043 0.038 DBMET00950 | ||
| 0.095 | 0.01 | 0.095 | Topoisomerase II beta inhibitor | 0.047 0.038 DBMET00949 | ||
| 0.089 | 0.005 | 0.089 | Histamine H2 receptor agonist | |||
| 0.148 | 0.064 | 0.148 | Cytokine production inhibitor | |||
| 0.123 | 0.04 | 0.123 | CDK2/cyclin A inhibitor | 0.087 0.071 DBMET00949 | ||
| 0.148 | 0.065 | 0.148 | MAP kinase kinase 4 inhibitor | |||
| 0.115 | 0.033 | 0.115 | Polo-like kinase-1 inhibitor | |||
| 0.122 | 0.04 | 0.122 | Sphingomyelinase inhibitor | |||
| 0.089 | 0.007 | 0.089 | Glucose-6-phosphate isomerase inhibitor | 0.047 0.035 DBMET00949 0.078 0.009 DBMET00950 | ||
| 0.139 | 0.057 | 0.139 | Antibacterial (Helicobacter pylori) | |||
| 0.088 | 0.007 | 0.088 | Sodium/calcium exchanger inhibitor | |||
| 0.099 | 0.018 | 0.099 | GP IIb/IIIa receptor antagonist | |||
| 0.119 | 0.038 | 0.119 | 5 Hydroxytryptamine 2A antagonist | |||
| 0.084 | 0.003 | 0.084 | Nicotinic alpha4beta2 receptor agonist | 0.065 0.004 DBMET00949 | ||
| 0.19 | 0.109 | 0.19 | Platelet antagonist | |||
| 0.156 | 0.075 | 0.156 | Anticoagulant | |||
| 0.089 | 0.009 | 0.093 | Lysine-specific demethylase 1A inhibitor | 0.093 0.008 DBMET00949 | DBMET00949 | |
| 0.094 | 0.014 | 0.094 | Glutamate (mGluR7) antagonist | |||
| 0.097 | 0.017 | 0.097 | Purinergic P2X1 antagonist | 0.057 0.048 DBMET00950 | ||
| 0.092 | 0.014 | 0.092 | Heat shock protein 90 beta antagonist | |||
| 0.154 | 0.076 | 0.154 | Melanin inhibitor | 0.127 0.12 DBMET00950 | ||
| 0.096 | 0.018 | 0.096 | Acetylcholine M5 receptor antagonist | 0.058 0.045 DBMET00949 | ||
| 0.082 | 0.005 | 0.082 | Vascular adhesion protein 1 inhibitor | |||
| 0.082 | 0.005 | 0.082 | Acetylcholine M4 receptor agonist | 0.04 0.015 DBMET00949 | ||
| 0.152 | 0.076 | 0.152 | Diuretic | |||
| 0.127 | 0.051 | 0.127 | GABA receptor agonist | |||
| 0.102 | 0.026 | 0.102 | GABA aminotransferase inhibitor | |||
| 0.091 | 0.016 | 0.091 | I kappa B kinase 2 inhibitor | 0.059 0.049 DBMET00949 | ||
| 0.078 | 0.003 | 0.078 | Nicotinic alpha3beta4 receptor agonist | 0.067 0.004 DBMET00949 | ||
| 0.085 | 0.011 | 0.085 | Acetylcholine M2 receptor agonist | 0.059 0.03 DBMET00949 | ||
| 0.093 | 0.019 | 0.093 | Beta adrenoreceptor antagonist | 0.062 0.051 DBMET00949 | ||
| 0.175 | 0.101 | 0.175 | Insulin sensitizer | |||
| 0.1 | 0.028 | 0.1 | Histone deacetylase SIRT1 stimulant | |||
| 0.1 | 0.028 | 0.1 | Histone deacetylase stimulant | |||
| 0.112 | 0.039 | 0.112 | NMDA receptor antagonist | 0.086 0.058 DBMET00949 | ||
| 0.093 | 0.02 | 0.093 | Dopamine uptake inhibitor | 0.065 0.034 DBMET00949 | ||
| 0.138 | 0.066 | 0.138 | Sodium channel blocker | |||
| 0.086 | 0.015 | 0.086 | Histone deacetylase SIRT3 inhibitor | |||
| 0.118 | 0.047 | 0.118 | Cyclin-dependent kinase 9 inhibitor | 0.096 0.067 DBMET00949 | ||
| 0.074 | 0.004 | 0.074 | Alpha 2d adrenoreceptor agonist | |||
| 0.085 | 0.015 | 0.085 | Beta 1 adrenoreceptor antagonist | |||
| 0.096 | 0.026 | 0.096 | CDC7 inhibitor | |||
| 0.074 | 0.004 | 0.074 | Protein kinase C beta II inhibitor | |||
| 0.097 | 0.028 | 0.097 | Polo-like kinase-2 inhibitor | |||
| 0.074 | 0.004 | 0.074 | Histamine H1 receptor agonist | 0.053 0.015 DBMET00949 | ||
| 0.092 | 0.023 | 0.092 | Secretase beta inhibitor | |||
| 0.129 | 0.06 | 0.129 | Anesthetic local | |||
| 0.076 | 0.007 | 0.076 | Histamine H3 receptor agonist | |||
| 0.074 | 0.006 | 0.074 | Potassium channel small-conductance Ca-activated activator | |||
| 0.102 | 0.034 | 0.102 | Alpha 1b adrenoreceptor antagonist | |||
| 0.141 | 0.073 | 0.141 | Glycogen synthase kinase-3 alpha inhibitor | |||
| 0.088 | 0.02 | 0.088 | Potassium channel (Tandem pore domain) blocker | |||
| 0.099 | 0.032 | 0.099 | NMDA 2 receptor antagonist | 0.074 0.048 DBMET00949 | ||
| 0.139 | 0.072 | 0.139 | Histone deacetylase SIRT1 inhibitor | |||
| 0.08 | 0.014 | 0.08 | Cyclin A1 inhibitor | 0.057 0.044 DBMET00949 | ||
| 0.089 | 0.022 | 0.089 | Acetylcholine M3 receptor antagonist | 0.061 0.04 DBMET00949 | ||
| 0.127 | 0.061 | 0.127 | MAP kinase 12 inhibitor | |||
| 0.071 | 0.004 | 0.071 | Protein kinase (CK2) beta inhibitor | 0.043 0.01 DBMET00949 | ||
| 0.081 | 0.015 | 0.081 | Phosphodiesterase 1A inhibitor | |||
| 0.083 | 0.017 | 0.083 | Phosphodiesterase 1C inhibitor | |||
| 0.072 | 0.007 | 0.072 | Geranyltranstransferase inhibitor | |||
| 0.156 | 0.09 | 0.156 | Interleukin-1 receptor-associated protein kinase 1 inhibitor | |||
| 0.077 | 0.012 | 0.077 | Dihydroorotate oxidase inhibitor | |||
| 0.07 | 0.004 | 0.07 | Kainate receptor agonist | 0.056 0.009 DBMET00949 0.046 0.019 DBMET00950 | ||
| 0.087 | 0.022 | 0.087 | Protease 3C (Human rhinovirus) inhibitor | 0.059 0.054 DBMET00949 | ||
| 0.071 | 0.006 | 0.071 | Acid-sensing ion channel blocker | |||
| 0.116 | 0.052 | 0.116 | AMP-activated protein kinase stimulant | |||
| 0.072 | 0.008 | 0.072 | Kainate receptor 2 antagonist | 0.031 0.029 DBMET00949 | ||
| 0.074 | 0.01 | 0.074 | CC chemokine receptor 2B antagonist | |||
| 0.074 | 0.01 | 0.074 | Pregnane X receptor antagonist | |||
| 0.116 | 0.053 | 0.116 | Expectorant | |||
| 0.07 | 0.007 | 0.07 | GABA uptake inhibitor | 0.055 0.012 DBMET00949 | ||
| 0.081 | 0.019 | 0.081 | NMDA 2A receptor antagonist | |||
| 0.07 | 0.008 | 0.07 | GABA B receptor antagonist | 0.049 0.021 DBMET00949 | ||
| 0.071 | 0.01 | 0.071 | Immunoglobulin Fc receptor antagonist | 0.052 0.049 DBMET00949 | ||
| 0.118 | 0.057 | 0.118 | MAP kinase 13 inhibitor | |||
| 0.103 | 0.041 | 0.103 | Phosphodiesterase I inhibitor | |||
| 0.095 | 0.035 | 0.095 | Rho-associated kinase I inhibitor | |||
| 0.071 | 0.011 | 0.071 | Potassium channel (Inward rectifier) activator | |||
| 0.074 | 0.014 | 0.074 | Nicotinic receptor alpha3 subunit antagonist | 0.056 0.021 DBMET00949 | ||
| 0.072 | 0.012 | 0.072 | Kainate receptor antagonist | |||
| 0.069 | 0.009 | 0.069 | GHS receptor agonist | 0.043 0.029 DBMET00949 | ||
| 0.103 | 0.043 | 0.103 | Bile acid receptor antagonist | 0.091 0.07 DBMET00949 | ||
| 0.08 | 0.02 | 0.08 | Pim-2 kinase inhibitor | |||
| 0.073 | 0.013 | 0.073 | Growth hormone secretagogue receptor agonist | |||
| 0.064 | 0.005 | 0.064 | Methionyl aminopeptidase 1 inhibitor | |||
| 0.068 | 0.009 | 0.068 | Fumarate hydratase inhibitor | 0.047 0.015 DBMET00950 | ||
| 0.074 | 0.015 | 0.074 | NMDA receptor subunit 3B antagonist | 0.048 0.026 DBMET00949 | ||
| 0.066 | 0.007 | 0.066 | Sphingosine kinase 1 inhibitor | 0.057 0.011 DBMET00949 0.047 0.019 DBMET00950 | ||
| 0.122 | 0.064 | 0.122 | Proteasome inhibitor | |||
| 0.066 | 0.008 | 0.066 | Arginase inhibitor | 0.053 0.013 DBMET00949 | ||
| 0.065 | 0.008 | 0.065 | Guanylate cyclase inhibitor | 0.044 0.028 DBMET00950 | ||
| 0.068 | 0.01 | 0.068 | Potassium channel (ATP-sensitive) activator | |||
| 0.098 | 0.04 | 0.098 | Carbonic anhydrase VI inhibitor | |||
| 0.064 | 0.006 | 0.064 | Hypoxanthine phosphoribosyltransferase inhibitor | 0.027 0.02 DBMET00949 0.024 0.023 DBMET00950 | ||
| 0.091 | 0.034 | 0.091 | Protein kinase B alpha inhibitor | |||
| 0.101 | 0.044 | 0.101 | Interleukin-1 receptor-associated protein kinase 4 inhibitor | 0.079 0.072 DBMET00949 | ||
| 0.073 | 0.016 | 0.073 | 5 Hydroxytryptamine 4 antagonist | 0.05 0.039 DBMET00949 | ||
| 0.08 | 0.023 | 0.08 | Beta 3 adrenoreceptor antagonist | 0.065 0.044 DBMET00949 | ||
| 0.063 | 0.007 | 0.063 | Protein kinase (CK1) epsilon inhibitor | |||
| 0.092 | 0.036 | 0.092 | Keratolytic | |||
| 0.071 | 0.016 | 0.071 | Beta 2 adrenoreceptor antagonist | 0.048 0.04 DBMET00949 | ||
| 0.065 | 0.01 | 0.065 | 5 Hydroxytryptamine 3B antagonist | 0.032 0.03 DBMET00949 | ||
| 0.11 | 0.055 | 0.11 | Urease inhibitor | |||
| 0.085 | 0.03 | 0.085 | Nav1.7 sodium channel blocker | |||
| 0.085 | 0.03 | 0.085 | Cyclin A2 inhibitor | 0.074 0.036 DBMET00949 | ||
| 0.061 | 0.007 | 0.061 | 3-Hydroxyanthranilate 3,4-dioxygenase inhibitor | |||
| 0.066 | 0.012 | 0.066 | Glutamate (mGluR4) antagonist | 0.054 0.018 DBMET00949 | ||
| 0.059 | 0.005 | 0.059 | CDK6/cyclin D3 inhibitor | |||
| 0.071 | 0.017 | 0.071 | Dipeptidyl peptidase inhibitor | 0.053 0.035 DBMET00949 | ||
| 0.098 | 0.044 | 0.098 | Alpha 1 adrenoreceptor antagonist | |||
| 0.074 | 0.021 | 0.074 | Nicotinic alpha7 receptor agonist | 0.049 0.044 DBMET00949 | ||
| 0.066 | 0.012 | 0.066 | CC chemokine 4 receptor antagonist | |||
| 0.057 | 0.004 | 0.057 | Myristoyl transferase inhibitor | 0.029 0.014 DBMET00949 | ||
| 0.075 | 0.023 | 0.075 | Enoyl-[acyl-carrier-protein] reductase inhibitor | |||
| 0.099 | 0.046 | 0.099 | Aminoacyl-tRNA synthetase inhibitor | |||
| 0.07 | 0.018 | 0.07 | Chemokine receptor agonist | |||
| 0.061 | 0.009 | 0.061 | Nerve growth factor antagonist | |||
| 0.056 | 0.004 | 0.056 | Histamine H4 receptor agonist | 0.021 0.01 DBMET00949 | ||
| 0.061 | 0.01 | 0.061 | AMPA 4 receptor antagonist | 0.05 0.015 DBMET00949 | ||
| 0.081 | 0.03 | 0.081 | Alpha 1d adrenoreceptor antagonist | |||
| 0.056 | 0.005 | 0.058 | Epoxide hydrolase 1 inhibitor | 0.058 0.005 DBMET00949 | DBMET00949 | |
| 0.107 | 0.056 | 0.107 | Gastric antisecretory | |||
| 0.066 | 0.016 | 0.066 | Adenosine deaminase inhibitor | 0.041 0.039 DBMET00950 | ||
| 0.076 | 0.026 | 0.097 | Androgen agonist | 0.097 0.016 DBMET00950 | DBMET00950 | |
| 0.171 | 0.12 | 0.171 | Aryl hydrocarbon receptor agonist | |||
| 0.06 | 0.01 | 0.06 | Diamine oxidase inhibitor | |||
| 0.08 | 0.03 | 0.08 | Acetylcholine M2 receptor antagonist | 0.065 0.041 DBMET00949 | ||
| 0.07 | 0.02 | 0.07 | Neurokinin antagonist | |||
| 0.058 | 0.008 | 0.058 | Glutamate (mGluR8) agonist | 0.04 0.022 DBMET00949 0.039 0.023 DBMET00950 | ||
| 0.107 | 0.058 | 0.107 | Protein kinase (CK2) inhibitor | |||
| 0.054 | 0.005 | 0.054 | Bombesin agonist | |||
| 0.057 | 0.008 | 0.057 | Endothelial nitric-oxide synthase inhibitor | 0.052 0.009 DBMET00949 | ||
| 0.1 | 0.052 | 0.1 | Alcohol dehydrogenase inhibitor | |||
| 0.053 | 0.004 | 0.053 | 5 Hydroxytryptamine 6 agonist | 0.031 0.015 DBMET00949 | ||
| 0.08 | 0.032 | 0.117 | Cyclin E inhibitor | 0.117 0.019 DBMET00949 | DBMET00949 | |
| 0.052 | 0.003 | 0.052 | Alpha 2c adrenoreceptor agonist | 0.017 0.016 DBMET00949 | ||
| 0.08 | 0.032 | 0.08 | Cyclin A inhibitor | 0.066 0.04 DBMET00949 | ||
| 0.056 | 0.008 | 0.056 | Integrin alpha2 antagonist | 0.042 0.018 DBMET00949 | ||
| 0.067 | 0.019 | 0.067 | Potassium channel (Inward rectifier) blocker | |||
| 0.058 | 0.011 | 0.058 | Membrane dipeptidase inhibitor | |||
| 0.051 | 0.003 | 0.051 | Alpha 2b adrenoreceptor agonist | |||
| 0.08 | 0.033 | 0.08 | Dopamine D1 antagonist | |||
| 0.072 | 0.025 | 0.072 | Calcium channel P-type blocker | 0.065 0.04 DBMET00950 | ||
| 0.083 | 0.036 | 0.083 | Phosphodiesterase VI inhibitor | |||
| 0.107 | 0.06 | 0.107 | MAP kinase kinase kinase inhibitor | |||
| 0.117 | 0.07 | 0.117 | TRKA antagonist | |||
| 0.082 | 0.035 | 0.082 | Sphingosine 1-phosphate receptor 4 agonist | |||
| 0.088 | 0.041 | 0.088 | Alpha 1a adrenoreceptor antagonist | |||
| 0.086 | 0.04 | 0.086 | Rho-associated kinase II inhibitor | |||
| 0.088 | 0.042 | 0.088 | 5 Hydroxytryptamine 1 antagonist | |||
| 0.076 | 0.03 | 0.076 | Aryl hydrocarbon receptor antagonist | |||
| 0.061 | 0.015 | 0.061 | Glutamate (mGluR1a) antagonist | |||
| 0.061 | 0.016 | 0.061 | Oxytocin agonist | 0.039 0.033 DBMET00949 | ||
| 0.062 | 0.016 | 0.062 | NMDA receptor subunit 3A antagonist | 0.035 0.029 DBMET00949 | ||
| 0.058 | 0.012 | 0.058 | Dihydropteroate synthase inhibitor | 0.037 0.03 DBMET00949 | ||
| 0.062 | 0.016 | 0.062 | Thymidylate synthase inhibitor | |||
| 0.06 | 0.014 | 0.06 | Neurokinin 1 antagonist | |||
| 0.141 | 0.096 | 0.141 | Heat shock protein 90 alpha antagonist | |||
| 0.087 | 0.042 | 0.087 | Focal adhesion kinase 1 inhibitor | |||
| 0.052 | 0.007 | 0.052 | Lysine carboxypeptidase inhibitor | 0.031 0.015 DBMET00949 | ||
| 0.088 | 0.043 | 0.088 | Transforming growth factor beta 3 antagonist | |||
| 0.051 | 0.007 | 0.051 | CDK4/cyclin D3 inhibitor | 0.033 0.014 DBMET00949 | ||
| 0.065 | 0.021 | 0.065 | Bombesin 2 receptor antagonist | |||
| 0.053 | 0.009 | 0.053 | 5 Hydroxytryptamine 1D agonist | 0.038 0.015 DBMET00949 | ||
| 0.049 | 0.005 | 0.049 | Bombesin 3 receptor agonist | |||
| 0.11 | 0.065 | 0.11 | EphA2 antagonist | |||
| 0.167 | 0.123 | 0.167 | Glucose-6-phosphate dehydrogenase-6-phosphogluconolactonase inhibitor | |||
| 0.048 | 0.004 | 0.048 | Estrogen-related receptor gamma antagonist | |||
| 0.15 | 0.106 | 0.15 | Platelet adhesion inhibitor | |||
| 0.072 | 0.028 | 0.072 | Phosphodiesterase 1B inhibitor | |||
| 0.114 | 0.071 | 0.114 | Cholesterol synthesis inhibitor | 0.108 0.077 DBMET00950 | ||
| 0.05 | 0.007 | 0.05 | Ceramide glucosyltransferase inhibitor | 0.037 0.021 DBMET00949 0.04 0.017 DBMET00950 | ||
| 0.056 | 0.012 | 0.056 | DNA gyrase subunit A inhibitor | 0.04 0.035 DBMET00949 | ||
| 0.07 | 0.027 | 0.07 | Potassium channel intermediate-conductance Ca-activated blocker | |||
| 0.06 | 0.017 | 0.06 | Potassium channel small-conductance Ca-activated blocker | |||
| 0.113 | 0.07 | 0.113 | Caspase 3 inhibitor | |||
| 0.058 | 0.015 | 0.058 | Thymidine kinase inhibitor | 0.043 0.026 DBMET00950 | ||
| 0.058 | 0.015 | 0.058 | Cytokine production stimulant | |||
| 0.094 | 0.051 | 0.094 | Ornithine decarboxylase inhibitor | |||
| 0.058 | 0.015 | 0.058 | AICAR transformylase inhibitor | 0.048 0.025 DBMET00950 | ||
| 0.057 | 0.014 | 0.057 | Dipeptidyl peptidase IV inhibitor | 0.044 0.032 DBMET00949 | ||
| 0.047 | 0.005 | 0.047 | Thymidine phosphorylase inhibitor | 0.024 0.023 DBMET00949 | ||
| 0.082 | 0.04 | 0.082 | Epoxide hydrolase inhibitor | 0.066 0.059 DBMET00949 | ||
| 0.09 | 0.048 | 0.09 | GABA A receptor agonist | |||
| 0.056 | 0.014 | 0.056 | Parathyroid hormone antagonist | |||
| 0.05 | 0.008 | 0.05 | Uridine phosphorylase inhibitor | |||
| 0.134 | 0.092 | 0.134 | Heat shock protein 90 antagonist | |||
| 0.046 | 0.005 | 0.046 | Protein kinase C beta I inhibitor | |||
| 0.087 | 0.046 | 0.087 | NAD(P)H dehydrogenase (quinone) inhibitor | |||
| 0.081 | 0.04 | 0.081 | 5 Hydroxytryptamine 1A antagonist | |||
| 0.069 | 0.028 | 0.069 | Carbonic anhydrase VB inhibitor | |||
| 0.048 | 0.007 | 0.048 | Transforming growth factor beta 2 antagonist | |||
| 0.044 | 0.004 | 0.044 | Acid ceramidase inhibitor | 0.026 0.016 DBMET00949 | ||
| 0.138 | 0.097 | 0.138 | Ca2+/calmodulin-dependent protein kinase kinase B inhibitor | |||
| 0.058 | 0.017 | 0.058 | CDK7/cyclin H inhibitor | |||
| 0.043 | 0.003 | 0.043 | Imidazoline I2 receptor antagonist | |||
| 0.074 | 0.034 | 0.074 | Potassium channel (ATP-sensitive) blocker | |||
| 0.044 | 0.005 | 0.044 | Glutamate (mGluR1a) agonist | |||
| 0.044 | 0.005 | 0.044 | Purinergic P2Y15 antagonist | 0.028 0.021 DBMET00949 0.034 0.011 DBMET00950 | ||
| 0.061 | 0.023 | 0.061 | Prolyl endopeptidase inhibitor | |||
| 0.089 | 0.05 | 0.089 | Leucine-rich repeat kinase 2 inhibitor | |||
| 0.112 | 0.074 | 0.112 | Calcium channel N-type blocker | |||
| 0.043 | 0.005 | 0.043 | MAP3K8 inhibitor | |||
| 0.066 | 0.028 | 0.066 | Beta 2 adrenoreceptor agonist | |||
| 0.065 | 0.028 | 0.065 | CC chemokine 2 receptor antagonist | |||
| 0.045 | 0.008 | 0.045 | Tryptophan 5 hydroxylase inhibitor | |||
| 0.045 | 0.009 | 0.045 | Purinergic P2Y14 antagonist | |||
| 0.08 | 0.044 | 0.08 | Cathepsin G inhibitor | |||
| 0.194 | 0.158 | 0.194 | 12-Lipoxygenase inhibitor | |||
| 0.05 | 0.013 | 0.05 | Prostacyclin antagonist | |||
| 0.234 | 0.198 | 0.234 | Analgesic | |||
| 0.101 | 0.065 | 0.101 | Nav1.1 sodium channel blocker | |||
| 0.049 | 0.013 | 0.049 | Potassium channel Kv1.1 blocker | |||
| 0.059 | 0.023 | 0.059 | Lysophosphatidic acid 3 receptor antagonist | |||
| 0.065 | 0.03 | 0.116 | Cyclin E1 inhibitor | 0.116 0.015 DBMET00949 | DBMET00949 | |
| 0.121 | 0.086 | 0.121 | Tyrosine-protein kinase receptor antagonist | |||
| 0.094 | 0.059 | 0.094 | Antihistaminic | |||
| 0.059 | 0.024 | 0.059 | Carbonic anhydrase II stimulant | |||
| 0.09 | 0.055 | 0.09 | Insulin growth factor antagonist | |||
| 0.057 | 0.022 | 0.057 | Aldosterone antagonist | |||
| 0.053 | 0.018 | 0.053 | Glutamate (mGluR group III) antagonist | 0.047 0.025 DBMET00949 | ||
| 0.067 | 0.033 | 0.067 | Glutamate (mGluR1) antagonist | |||
| 0.065 | 0.031 | 0.065 | Botulinum neurotoxin type A inhibitor | |||
| 0.043 | 0.009 | 0.043 | Estrogen-related receptor beta antagonist | |||
| 0.04 | 0.007 | 0.04 | Kainate receptor 1 antagonist | |||
| 0.076 | 0.043 | 0.076 | Benzodiazepine agonist | |||
| 0.044 | 0.011 | 0.044 | Cyclin E2 inhibitor | |||
| 0.057 | 0.024 | 0.057 | Squalene epoxidase inhibitor | |||
| 0.061 | 0.028 | 0.061 | 3(or 17)beta-hydroxysteroid dehydrogenase inhibitor | |||
| 0.069 | 0.036 | 0.069 | Phosphodiesterase VII inhibitor | |||
| 0.105 | 0.072 | 0.105 | Monophenol monooxygenase inhibitor | |||
| 0.043 | 0.011 | 0.043 | Lysophosphatidic acid 2 receptor antagonist | |||
| 0.036 | 0.004 | 0.036 | Complement factor 1s inhibitor | |||
| 0.093 | 0.061 | 0.093 | Potassium channel (Ca-activated) activator | |||
| 0.041 | 0.009 | 0.041 | NMDA 2D receptor antagonist | |||
| 0.062 | 0.03 | 0.062 | GABA receptor antagonist | |||
| 0.085 | 0.054 | 0.085 | Insulin like growth factor 1 antagonist | |||
| 0.036 | 0.004 | 0.036 | Cyclin T1 inhibitor | 0.03 0.005 DBMET00949 | ||
| 0.066 | 0.035 | 0.066 | Plasminogen activator inhibitor | |||
| 0.037 | 0.006 | 0.037 | Nicotinic acid receptor 2 antagonist | |||
| 0.045 | 0.015 | 0.045 | Somatostatin 5 agonist | |||
| 0.053 | 0.022 | 0.053 | Dihydroorotase inhibitor | |||
| 0.036 | 0.005 | 0.036 | Glutaminyl-peptide cyclotransferase inhibitor | |||
| 0.073 | 0.042 | 0.073 | Dopamine agonist | |||
| 0.049 | 0.018 | 0.049 | Renin inhibitor | |||
| 0.055 | 0.025 | 0.055 | HCV NS3/NS4A protease inhibitor | |||
| 0.096 | 0.067 | 0.096 | Insulin receptor antagonist | |||
| 0.113 | 0.083 | 0.113 | TRKB antagonist | |||
| 0.1 | 0.071 | 0.1 | Granulocyte macrophage colony stimulating factor antagonist | |||
| 0.047 | 0.018 | 0.047 | Heme oxygenase inhibitor | |||
| 0.078 | 0.049 | 0.078 | MAP kinase 11 inhibitor | |||
| 0.045 | 0.016 | 0.045 | Phosphoglycerate kinase inhibitor | |||
| 0.057 | 0.028 | 0.057 | Heparanase inhibitor | |||
| 0.036 | 0.007 | 0.036 | Glutamate (mGluR1) agonist | 0.027 0.013 DBMET00949 | ||
| 0.092 | 0.064 | 0.092 | Fibroblast growth factor 1 antagonist | |||
| 0.074 | 0.045 | 0.074 | Orexin receptor 1 antagonist | |||
| 0.072 | 0.044 | 0.072 | Carbonic anhydrase VA inhibitor | |||
| 0.044 | 0.015 | 0.044 | Somatostatin agonist | |||
| 0.08 | 0.051 | 0.08 | Fibroblast growth factor 3 antagonist | |||
| 0.117 | 0.088 | 0.117 | Bone formation stimulant | |||
| 0.039 | 0.011 | 0.039 | Glutamate (mGluR3) agonist | 0.031 0.027 DBMET00949 | ||
| 0.062 | 0.033 | 0.062 | Fatty acid synthase inhibitor | |||
| 0.073 | 0.045 | 0.073 | CDK2/cyclin E2 inhibitor | 0.068 0.05 DBMET00949 | ||
| 0.047 | 0.019 | 0.047 | Substance P antagonist | |||
| 0.062 | 0.035 | 0.062 | Sphingosine 1-phosphate receptor 3 antagonist | |||
| 0.079 | 0.052 | 0.08 | Somatostatin 1 agonist | 0.08 0.051 DBMET00949 | DBMET00949 | |
| 0.079 | 0.052 | 0.079 | CC chemokine receptor antagonist | |||
| 0.04 | 0.013 | 0.04 | Melatonin receptor 1A agonist | |||
| 0.034 | 0.007 | 0.034 | Glucosylceramidase stimulant | |||
| 0.031 | 0.004 | 0.031 | Carbonic anhydrase X inhibitor | |||
| 0.031 | 0.004 | 0.031 | Carbonic anhydrase VIII inhibitor | |||
| 0.041 | 0.014 | 0.041 | CXC chemokine receptor agonist | |||
| 0.066 | 0.039 | 0.066 | Transcription factor RelA inhibitor | |||
| 0.117 | 0.091 | 0.117 | Calcium channel blocker | |||
| 0.085 | 0.059 | 0.085 | Histamine antagonist | |||
| 0.043 | 0.017 | 0.043 | Glutamate (mGluR3) antagonist | 0.036 0.026 DBMET00950 | ||
| 0.062 | 0.036 | 0.062 | Cathepsin L inhibitor | |||
| 0.105 | 0.079 | 0.105 | CDK3/cyclin E inhibitor | |||
| 0.034 | 0.008 | 0.034 | Thymidine kinase (Herpes simplex virus 1) inhibitor | 0.028 0.015 DBMET00950 | ||
| 0.109 | 0.083 | 0.109 | Protein kinase (CK1) delta inhibitor | |||
| 0.058 | 0.032 | 0.058 | GABA A receptor antagonist | |||
| 0.039 | 0.014 | 0.039 | ATR kinase inhibitor | 0.031 0.026 DBMET00949 | ||
| 0.03 | 0.005 | 0.03 | Factor XIII inhibitor | |||
| 0.039 | 0.014 | 0.039 | AMPA 3 receptor antagonist | 0.031 0.019 DBMET00949 | ||
| 0.051 | 0.026 | 0.051 | Purinergic P2Y antagonist | |||
| 0.188 | 0.163 | 0.188 | MAP kinase kinase 3 inhibitor | |||
| 0.073 | 0.048 | 0.073 | Calcium channel L-type blocker | |||
| 0.035 | 0.011 | 0.035 | Methionyl aminopeptidase 2 inhibitor | |||
| 0.034 | 0.01 | 0.034 | Calcium-sensing receptor agonist | |||
| 0.055 | 0.03 | 0.055 | Phosphodiesterase 7A inhibitor | |||
| 0.033 | 0.009 | 0.033 | Hedgehog signaling activator | 0.027 0.021 DBMET00950 | ||
| 0.029 | 0.005 | 0.029 | Thymidine kinase (Herpes simplex virus 2) inhibitor | 0.021 0.013 DBMET00950 | ||
| 0.044 | 0.02 | 0.044 | Nicotinic receptor beta4 subunit antagonist | |||
| 0.155 | 0.131 | 0.155 | MAP kinase kinase 5 inhibitor | |||
| 0.075 | 0.051 | 0.075 | Adenosine A3 receptor antagonist | |||
| 0.067 | 0.043 | 0.067 | Neutrophil collagenase inhibitor | |||
| 0.127 | 0.104 | 0.127 | Tyrosine kinase inhibitor | |||
| 0.044 | 0.02 | 0.044 | Carbonic anhydrase I stimulant | |||
| 0.032 | 0.009 | 0.032 | Lysophosphatidic acid receptor 1 agonist | |||
| 0.038 | 0.015 | 0.038 | Dipeptidyl peptidase II inhibitor | 0.036 0.018 DBMET00949 | ||
| 0.026 | 0.003 | 0.026 | Cyclin D2 inhibitor | 0.014 0.008 DBMET00949 | ||
| 0.033 | 0.01 | 0.033 | Integrin alpha2beta1 antagonist | |||
| 0.031 | 0.008 | 0.031 | Vanilloid 2 agonist | 0.024 0.022 DBMET00950 | ||
| 0.084 | 0.061 | 0.084 | Hematopoietic | |||
| 0.145 | 0.122 | 0.145 | Non-steroidal antiinflammatory agent | |||
| 0.038 | 0.015 | 0.038 | Adenosine uptake inhibitor | |||
| 0.075 | 0.053 | 0.075 | Carbonic anhydrase XIII inhibitor | |||
| 0.083 | 0.061 | 0.083 | Bcr-Abl kinase inhibitor | |||
| 0.041 | 0.02 | 0.041 | Delayed rectifier potassium channel blocker | |||
| 0.052 | 0.03 | 0.052 | Antimetabolite | |||
| 0.099 | 0.077 | 0.099 | Protein kinase (CK2) alpha inhibitor | |||
| 0.034 | 0.013 | 0.034 | DNA topoisomerase IV inhibitor | |||
| 0.026 | 0.005 | 0.026 | Histone-lysine N-methyltransferase EZH2 inhibitor | |||
| 0.091 | 0.07 | 0.091 | MAO A inhibitor | |||
| 0.037 | 0.016 | 0.037 | Peptide deformylase inhibitor | |||
| 0.036 | 0.015 | 0.036 | Vanilloid 4 antagonist | |||
| 0.05 | 0.029 | 0.05 | Cholesterol esterase inhibitor | |||
| 0.073 | 0.053 | 0.073 | Janus tyrosine kinase 2 inhibitor | |||
| 0.042 | 0.022 | 0.042 | MAP3K5 inhibitor | |||
| 0.038 | 0.018 | 0.038 | Carnitine palmitoyltransferase 1 inhibitor | |||
| 0.072 | 0.052 | 0.072 | Metalloproteinase-9 inhibitor | |||
| 0.086 | 0.066 | 0.086 | Potassium channel activator | |||
| 0.066 | 0.046 | 0.066 | Carbonic anhydrase V inhibitor | |||
| 0.076 | 0.056 | 0.076 | Estrogen receptor alpha antagonist | |||
| 0.038 | 0.018 | 0.038 | Carnitine palmitoyltransferase inhibitor | |||
| 0.028 | 0.009 | 0.028 | 5 Hydroxytryptamine 4 agonist | 0.027 0.01 DBMET00949 | ||
| 0.043 | 0.024 | 0.043 | Cathepsin L1 inhibitor | |||
| 0.071 | 0.052 | 0.071 | Macrophage colony-stimulating factor 1 receptor antagonist | |||
| 0.032 | 0.013 | 0.032 | CXC chemokine 2 receptor antagonist | |||
| 0.041 | 0.022 | 0.041 | CF transmembrane conductance regulator antagonist | 0.039 0.029 DBMET00950 | ||
| 0.053 | 0.035 | 0.053 | mTOR inhibitor | |||
| 0.022 | 0.005 | 0.022 | CXC chemokine 4 receptor agonist | 0.015 0.011 DBMET00949 | ||
| 0.044 | 0.027 | 0.044 | Toll-Like receptor 2 agonist | |||
| 0.031 | 0.014 | 0.031 | LFA antagonist | |||
| 0.034 | 0.018 | 0.034 | AMPA 1 receptor antagonist | |||
| 0.026 | 0.01 | 0.026 | ICAM 1 antagonist | |||
| 0.025 | 0.008 | 0.025 | Neuraminidase (Influenza B) inhibitor | |||
| 0.048 | 0.032 | 0.048 | Glutamate (mGluR group I) agonist | |||
| 0.05 | 0.034 | 0.05 | Transforming growth factor beta 1 antagonist | |||
| 0.088 | 0.072 | 0.088 | Potassium channel (Voltage-sensitive) activator | |||
| 0.021 | 0.005 | 0.021 | CDK2/cyclin A3 inhibitor | |||
| 0.035 | 0.019 | 0.035 | Carboxypeptidase B inhibitor | 0.031 0.027 DBMET00949 | ||
| 0.022 | 0.006 | 0.022 | Methylmalonyl-CoA mutase inhibitor | 0.018 0.014 DBMET00950 | ||
| 0.068 | 0.053 | 0.068 | Phosphodiesterase V inhibitor | |||
| 0.039 | 0.024 | 0.039 | Factor XIIIa inhibitor | |||
| 0.058 | 0.043 | 0.058 | Collagenase 3 inhibitor | |||
| 0.055 | 0.04 | 0.055 | MAP kinase kinase 9 inhibitor | |||
| 0.039 | 0.024 | 0.039 | Vanilloid 3 antagonist | |||
| 0.046 | 0.031 | 0.046 | Glutamate (mGluR5) agonist | |||
| 0.039 | 0.025 | 0.039 | DNA gyrase subunit B inhibitor | |||
| 0.076 | 0.062 | 0.076 | Histamine H1 receptor antagonist | |||
| 0.036 | 0.022 | 0.036 | Calcitonin receptor agonist | |||
| 0.025 | 0.011 | 0.025 | Protease (Human cytomegalovirus) inhibitor | |||
| 0.021 | 0.007 | 0.021 | Complement factor D inhibitor | |||
| 0.213 | 0.199 | 0.213 | 15-Lipoxygenase inhibitor | |||
| 0.039 | 0.025 | 0.039 | Melanocortin 1 antagonist | |||
| 0.036 | 0.023 | 0.036 | Opioid delta receptor agonist | |||
| 0.02 | 0.007 | 0.02 | NMDA receptor phencyclidine site antagonist | |||
| 0.018 | 0.005 | 0.018 | Carbonic anhydrase XI inhibitor | |||
| 0.02 | 0.007 | 0.02 | Telomerase stimulant | 0.019 0.009 DBMET00950 | ||
| 0.045 | 0.032 | 0.045 | Fructose-1,6-bisphosphatase inhibitor | |||
| 0.021 | 0.009 | 0.021 | Estrogen-related receptor gamma agonist | |||
| 0.075 | 0.063 | 0.075 | MAP kinase 7 inhibitor | |||
| 0.069 | 0.057 | 0.069 | Nav1.8 sodium channel blocker | |||
| 0.066 | 0.054 | 0.066 | Transforming growth factor antagonist | |||
| 0.079 | 0.067 | 0.079 | Androgen antagonist | |||
| 0.052 | 0.04 | 0.052 | Ribonucleoside-diphosphate reductase inhibitor | |||
| 0.021 | 0.009 | 0.021 | Antibiotic Anthracycline-like | 0.018 0.014 DBMET00950 | ||
| 0.053 | 0.041 | 0.053 | Ribonucleotide reductase inhibitor | |||
| 0.077 | 0.066 | 0.077 | Glutathione S-transferase inhibitor | |||
| 0.079 | 0.068 | 0.079 | T cell inhibitor | |||
| 0.056 | 0.044 | 0.056 | Calcium channel T-type blocker | |||
| 0.022 | 0.011 | 0.022 | Toll-Like receptor 8 agonist | |||
| 0.061 | 0.051 | 0.061 | Fibroblast growth factor 2 antagonist | |||
| 0.058 | 0.047 | 0.058 | Dopamine D3 antagonist | |||
| 0.072 | 0.062 | 0.072 | Metalloproteinase-2 inhibitor | |||
| 0.018 | 0.008 | 0.018 | Thromboxane A2 agonist | 0.016 0.01 DBMET00950 | ||
| 0.06 | 0.05 | 0.068 | Prolactin release inhibitor | 0.068 0.026 DBMET00950 | DBMET00950 | |
| 0.024 | 0.014 | 0.024 | Isoleucine-tRNA ligase inhibitor | |||
| 0.065 | 0.055 | 0.065 | Syk tyrosine kinase inhibitor | 0.062 0.058 DBMET00949 | ||
| 0.028 | 0.019 | 0.028 | 11-Beta-hydroxysteroid dehydrogenase 2 inhibitor | |||
| 0.096 | 0.087 | 0.096 | Aurora-B kinase inhibitor | |||
| 0.016 | 0.007 | 0.016 | Lysophosphatidic acid receptor 3 agonist | |||
| 0.015 | 0.006 | 0.015 | 1-Deoxy-D-xylulose-5-phosphate reductoisomerase inhibitor | |||
| 0.045 | 0.037 | 0.045 | AMPA receptor antagonist | |||
| 0.042 | 0.034 | 0.042 | Stearoyl-CoA desaturase inhibitor | |||
| 0.062 | 0.054 | 0.062 | Orexin receptor antagonist | |||
| 0.035 | 0.027 | 0.035 | Nicotinic acid receptor agonist | |||
| 0.011 | 0.003 | 0.011 | DNA topoisomerase III inhibitor | |||
| 0.017 | 0.009 | 0.017 | Purinergic P2Y1 agonist | |||
| 0.064 | 0.057 | 0.064 | Phosphodiesterase 5A inhibitor | |||
| 0.037 | 0.03 | 0.037 | Histone deacetylase 9 inhibitor | |||
| 0.099 | 0.092 | 0.099 | MAO inhibitor | |||
| 0.022 | 0.015 | 0.022 | Adenosine kinase inhibitor | |||
| 0.046 | 0.039 | 0.046 | Adenosine A2b receptor antagonist | |||
| 0.075 | 0.068 | 0.075 | AXL receptor tyrosine kinase inhibitor | |||
| 0.045 | 0.039 | 0.045 | Benzodiazepine antagonist | |||
| 0.013 | 0.007 | 0.013 | Glutamate (mGluR6) agonist | |||
| 0.027 | 0.021 | 0.027 | Thrombin receptor antagonist | |||
| 0.064 | 0.059 | 0.064 | Dopamine antagonist | |||
| 0.137 | 0.132 | 0.137 | Dual specificity tyrosine-phosphorylation regulated kinase 3 inhibitor | |||
| 0.012 | 0.007 | 0.012 | Purine nucleoside phosphorylase inhibitor | |||
| 0.135 | 0.13 | 0.135 | Pyruvate kinase inhibitor | |||
| 0.029 | 0.024 | 0.029 | Dipeptidyl peptidase I inhibitor | |||
| 0.022 | 0.018 | 0.022 | Dopamine autoreceptor agonist | |||
| 0.039 | 0.034 | 0.039 | Sphingosine 1-phosphate receptor 1 agonist | |||
| 0.039 | 0.034 | 0.039 | Plasmepsin II inhibitor | |||
| 0.013 | 0.008 | 0.013 | Integrin beta2 antagonist | |||
| 0.029 | 0.025 | 0.029 | Cholesterol ester transfer protein antagonist | |||
| 0.127 | 0.123 | 0.127 | TRKC antagonist | |||
| 0.12 | 0.116 | 0.12 | Ca2+/calmodulin-dependent kinase II gamma inhibitor | |||
| 0.008 | 0.004 | 0.008 | Integrin alpha5beta6 antagonist | |||
| 0.007 | 0.004 | 0.007 | CC chemokine 6 receptor agonist | 0.006 0.005 DBMET00949 | ||
| 0.011 | 0.008 | 0.011 | Melatonin 5 antagonist | |||
| 0.053 | 0.05 | 0.053 | Leukotriene C antagonist | |||
| 0.066 | 0.063 | 0.066 | Protein kinase B gamma inhibitor | |||
| 0.016 | 0.014 | 0.016 | Nicotinic acid receptor 1 antagonist | |||
| 0.022 | 0.02 | 0.022 | Fructose-1,6-bisphosphatase 1 inhibitor | |||
| 0.062 | 0.06 | 0.062 | Janus tyrosine kinase 3 inhibitor | |||
| 0.052 | 0.049 | 0.052 | Sphingosine 1-phosphate receptor 1 antagonist | |||
| 0.033 | 0.03 | 0.033 | Histone deacetylase 7 inhibitor | |||
| 0.024 | 0.022 | 0.024 | Sodium/glucose cotransporter inhibitor | |||
| 0.037 | 0.035 | 0.037 | CDK5/p25 inhibitor | |||
| 0.054 | 0.052 | 0.056 | CDK1/cyclin B inhibitor | 0.056 0.05 DBMET00949 | DBMET00949 | |
| 0.049 | 0.048 | 0.049 | Matrix metalloproteinase (membrane-type) inhibitor | |||
| 0.014 | 0.012 | 0.014 | Adenosine A2a receptor agonist | |||
| 0.043 | 0.041 | 0.043 | Beta adrenoreceptor agonist | |||
| 0.022 | 0.02 | 0.022 | NMDA receptor glycine site antagonist | |||
| 0.015 | 0.014 | 0.015 | Adenosine A2 receptor agonist | |||
| 0.037 | 0.036 | 0.037 | Histamine H3 receptor antagonist | |||
| 0.011 | 0.01 | 0.011 | Egl nine homolog 3 inhibitor | |||
| 0.01 | 0.009 | 0.01 | Purinergic P2Y2 agonist | |||
| 0.011 | 0.01 | 0.011 | Melatonin 2 antagonist | |||
| 0.009 | 0.008 | 0.009 | Progesterone receptor A antagonist | |||
| 0.004 | 0.003 | 0.004 | Reverse transcriptase (HBV) inhibitor | |||
| 0.013 | 0.012 | 0.013 | Integrin alphaVbeta6 antagonist | |||
| 0.035 | 0.04 | 0.04 | Integrin alpha1beta1 antagonist | 0.04 0.021 DBMET00949 | DBMET00949 | |
| 0.062 | 0.108 | 0.155 | Dual specificity tyrosine-phosphorylation regulated kinase 2 inhibitor | 0.155 0.013 DBMET00949 | DBMET00949 | |
| 0.012 | 0.068 | 0.045 | AMPA 2 receptor antagonist | 0.045 0.012 DBMET00949 | DBMET00949 | |
| 0.144 | 0.211 | 0.196 | Peptidyltransferase inhibitor | 0.196 0.105 DBMET00950 | DBMET00950 | |
| 0.05 | 0.16 | 0.179 | MAP kinase 9 inhibitor | 0.179 0.028 DBMET00949 | DBMET00949 | |
| 0.012 | 0.129 | 0.04 | 1,3-Beta-glucan synthase inhibitor | 0.04 0.004 DBMET00950 | DBMET00950 | |
| 0.048 | 0.168 | 0.159 | Cyclin-dependent kinase 5 inhibitor | 0.159 0.036 DBMET00949 | DBMET00949 | |
| 0.081 | 0.213 | 0.145 | Sigma receptor agonist | 0.145 0.088 DBMET00950 | DBMET00950 | |
| 0.033 | 0.173 | 0.182 | MAP kinase 10 inhibitor | 0.182 0.011 DBMET00949 | DBMET00949 | |
| 0.018 | 0.195 | 0.039 | Antibiotic Aminoglycoside-like | 0.039 0.021 DBMET00950 | DBMET00950 | |
| 0.054 | 0.257 | 0.078 | 3C-Like protease (SARS coronavirus) inhibitor | 0.078 0.077 DBMET00949 | DBMET00949 | |
| 0.009 | 0.259 | 0.072 | Opioid kappa receptor agonist | 0.072 0.014 DBMET00950 | DBMET00950 | |
| 0.02 | 0.309 | 0.08 | MAP kinase kinase 10 inhibitor | 0.08 0.029 DBMET00949 | DBMET00949 | |
| 0.055 | 0.39 | 0.152 | Hepatoprotectant | 0.152 0.108 DBMET00950 | DBMET00950 | |
| 0.076 | 0.479 | 0.204 | Sodium/bile acid cotransporter inhibitor | 0.204 0.183 DBMET00950 | DBMET00950 | |
| 0.012 | 0.496 | 0.399 | Nitric oxide donor | 0.065 0.04 DBMET00949 0.399 0.001 DBMET00950 | DBMET00950 | |
| 0.019 | 0.586 | 0.273 | Angiogenesis stimulant | 0.273 0.06 DBMET00950 | DBMET00950 | |
| 0.003 | 0.739 | 0.046 | Adenosine A1 receptor agonist | 0.046 0.006 DBMET00950 | DBMET00950 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |